


## Almonertinib mesylate

<b>Cat. No.:</b>	HY-112823A
<b>CAS No.:</b>	2134096-06-1
<b>Molecular Formula:</b>	C <sub>31</sub> H <sub>39</sub> N <sub>7</sub> O <sub>5</sub> S
<b>Molecular Weight:</b>	621.75
<b>Target:</b>	EGFR
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 31.25 mg/mL (50.26 mM; ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.6084 mL	8.0418 mL	16.0836 mL
	5 mM	0.3217 mL	1.6084 mL	3.2167 mL
	10 mM	0.1608 mL	0.8042 mL	1.6084 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC<sub>50</sub>: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer<sup>[1][2]</sup>.

#### In Vitro

HS-10296 mesylate is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity, which can be used to treat NSCLC<sup>[2]</sup>. Additionally, HS-10296 mesylate could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q<sup>[3]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- Front Pharmacol. 2021 May 14;12:671328.
- Patent. US20220177473A1.

---

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. *J Thorac Oncol.* 2020;S1556-0

[2]. Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. *Front Med (Lausanne).* 2017 Jan 18;3:76.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA